FDA Approves SOLIRIS — Alexion Pharmaceuticals Inc.

FDA approval of Alexion Pharmaceuticals Inc.’s (NASDAQ: ALXN) SOLIRIS (eculizumab) treatment represents a landmark milestone in targeted medicine, fundamentally establishing the target of complement-mediated diseases as a viable and lucrative therapeutic class. This landmark authorization, granted over 16 years ago on March 16, 2007, serves as the foundational event that initiated the growing market for complement inhibitors and solidified the company’s status as a pioneer in rare disease treatment.